CardiovascularORALGeneric

LIPTRUZET

ATORVASTATIN CALCIUM; EZETIMIBE

Standard Dose

EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview LIPTRUZET is listed in Drugs@FDA under application 200153 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ATORVASTATIN CALCIUM; EZETIMIBE Form and strength TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2024-10-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview LIPTRUZET is listed in Drugs@FDA under application 200153 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ATORVASTATIN CALCIUM; EZETIMIBE Form and strength TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2024-10-28 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.